Short answer
Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on May 18, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Initial Phase 1 CLN-978 data scheduled for June EULAR presentation.
Cullinan Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Initial Phase 1 CLN-978 data scheduled for June EULAR presentation
- OUTRACE targets treatment-refractory rheumatoid arthritis and moderate-to-severe systemic lupus erythematosus
- Clinical readout could influence investor assessment of CLN-978’s efficacy, safety, and development potential
- Full announcement furnished as Exhibit 99.1
Item 8.01 · Other Events
- Phase 1 CLN-978 data covered 14 treatment-refractory RA and SLE patients as of January 14, 2026
- B-cell depletion exceeded 75% in 9 of 11 patients after 10 mcg dosing
- At 20 mcg, three of six patients achieved B-cell depletion below quantification
- Four of five RA patients improved DAS28-ESR, including one remission and three moderate-activity outcomes
- Five of six SLE patients reduced SLEDAI scores by more than 4 points; updated data expected at EULAR in June 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cullinan Therapeutics, Inc. 8-K filings
Get the next CGEM 8-K as it lands
Follow CGEM for push alerts, or ask the research agent what this filing means.